Comprehensive Preimplantation Genetic Testing (PGT) Notes
Reproductive Options for Inherited Genetic Disorders
Spectrum of Reproductive Options: Couples at risk of transmitting an inherited genetic disorder have multiple pathways to consider:
- Premarital or preconception carrier screening to evaluate partner risks.
- Taking the reproductive chance naturally without medical intervention.
- Choosing to remain childless.
- Traditional prenatal diagnosis (PND) during pregnancy.
- Preimplantation genetic testing (PGT) in conjunction with in vitro fertilisation (IVF).
- Utilising donor gametes (donor sperm, donor oocytes, or double donation).
- Adoption.
Factors Influencing Decision-Making:
- Penetrance: Whether individuals with the pathogenic variant will definitively manifest clinical symptoms.
- Expressivity and Age of Onset: Variability in clinical severity, symptoms, and whether the disorder is congenital, childhood-onset, or adult-onset.
- Available Medical Interventions: Presence of effective therapies or requirements for lifelong palliative care.
- Prophylactic Surgery: Potential requirement for radical preventive procedures (e.g., bilateral mastectomy or oophorectomy for BRCA1/2 carriers).
- Religious and Moral Convictions: Beliefs regarding the moral status of early human embryos versus termination of established pregnancies.
- Infertility History: Baseline fecundity and whether fertility treatment is already clinically indicated.
- Personal Lived Experience: Family history, previous experience caring for an affected child or relative, and psychological trauma from prior terminations.
Prenatal Diagnosis (PND) Timelines and Modalities:
- Cell-Free Fetal DNA (cffDNA): Non-invasive maternal plasma sampling performed from approximately weeks of gestation.
- Chorionic Villus Sampling (CVS): Transabdominal or transcervical placental biopsy performed between and weeks of gestation.
- Amniocentesis: Aspiration of amniotic fluid containing fetal amniocytes performed between and weeks of gestation.
- Fetal Blood Sampling (Cordocentesis): Direct aspiration from the umbilical vein performed from weeks of gestation onward.
- Clinical Consequence: A definitive diagnosis of an affected fetus via traditional PND leaves the prospective parents with the difficult decision of whether or not to proceed with a therapeutic termination of pregnancy.
Preimplantation Genetic Testing Alternative: PGT is performed on early-stage preimplantation human embryos generated through IVF, enabling the selective transfer of unaffected embryos to initiate a pregnancy and thereby avoiding therapeutic termination.
Classification and Scope of Preimplantation Genetic Testing (PGT)
Regulatory Framework: In the United Kingdom, PGT is strictly regulated by the statutory body, the Human Fertilisation and Embryology Authority (HFEA). Clinics must hold specific regulatory permission from the HFEA to test for each specific monogenic condition.
Nomenclature Standardization: As defined in The International Glossary on Infertility and Fertility Care (2017) (Zegers-Hochschild et al., Human Reproduction, 2017), historical terms like PGD (Preimplantation Genetic Diagnosis) and PGS (Preimplantation Genetic Screening) have been formally redefined into three specific clinical categories:
PGT for Monogenic/Single Gene Defects (PGT-M):
- Primary Aim: To identify and select genetically normal embryos for couples at high risk of transmitting an identified single-gene mutation.
- Patient Demographic: Typically fertile couples where one or both partners carry a germline pathogenic variant (autosomal dominant, autosomal recessive, or X-linked).
- Key Clinical Contexts: Severe monogenic disease, personal/ethical objections to abortion, history of repeated terminations of affected fetuses, or creating a "saviour sibling" via Human Leukocyte Antigen (HLA) typing.
- Clinical Outcome: Undiagnosed embryos or embryos carrying the pathogenic variant are not transferred; ethically and clinically relatively uncontroversial.
PGT for Chromosomal Structural Rearrangements (PGT-SR):
- Primary Aim: To distinguish embryos with a normal or balanced chromosomal complement from those that have inherited unbalanced chromosomal material.
- Patient Demographic: Typically couples in which one partner carries a balanced structural rearrangement (e.g., reciprocal translocations, Robertsonian translocations, or chromosomal inversions).
- Clinical Indications: Subfertility, recurrent miscarriages, and repeated IVF implantation failures caused by unbalanced meiotic segregation.
- Clinical Outcome: Embryos bearing unbalanced chromosomal translocations are eliminated, allowing the transfer of euploid or balanced embryos; uncontroversial.

- PGT for Aneuploidies (PGT-A):
- Primary Aim: To assess whether embryos are chromosomally normal (euploid) to facilitate successful implantation and sustain pregnancy to full-term live birth.
- Patient Demographic: Infertile or subfertile patients undergoing assisted reproduction who possess normal constitutional karyotypes.
- Clinical Indications:
- Recurrent pregnancy loss / recurrent miscarriage with normal parental karyotypes.
- Recurrent IVF failure ( unsuccessful embryo transfers).
- Advanced maternal age (maternal age or years).
- Severe male factor infertility.
- Clinical Outcome and Controversies: Aneuploid embryos are discarded; undiagnosed embryos or embryos exhibiting chromosomal mosaicism may sometimes be considered for transfer. It remains controversial within reproductive medicine whether PGT-A consistently improves cumulative live birth rates across all patient demographics.
In Vitro Fertilisation and Embryo Biopsy Modalities
Procedural Sequence in PGT:
- Superovulation and oocyte retrieval.
- Insemination and fertilisation via IVF or Intracytoplasmic Sperm Injection (ICSI).
- In vitro embryo culture.
- Micromanipulation and cellular biopsy.
- Genetic diagnosis using cytogenetic or molecular platforms.
- Transfer of selected unaffected, euploid embryo(s).
Fertilisation Requirement (ICSI): Intracytoplasmic Sperm Injection (ICSI) is preferred over standard IVF insemination for molecular PGT cycles because standard IVF leaves extraneous, non-fertilising sperm and surrounding cumulus cells embedded in the zona pellucida, which can lead to paternal or maternal DNA contamination during single-cell PCR amplification.

Polar Body Biopsy:
- Timing: Removal of the first polar body (PBI) from unfertilised or recently retrieved oocytes, and/or removal of the second polar body (PBII) from the human zygote ( post-fertilisation).
- Advantages: Completely non-invasive to the embryonic developmental lineage, as polar bodies degenerate and do not contribute to fetal or placental development.
- Limitations: Only reflects maternal meiotic segregation errors and mutations; completely blind to paternally transmitted mutations or post-zygotic mitotic segregation errors.
Cleavage-Stage Biopsy (Day 3):
- Timing: Performed at approximately post-insemination on an 8-cell embryo.
- Procedure: A hole is breeched in the zona pellucida (using acid Tyrode's solution or a targeted infrared laser), and nucleated blastomeres are aspirated using a biopsy micropipette.
- Limitations: Significant cellular reduction ( of embryonic mass), which may reduce embryonic developmental potential; high prevalence of chromosomal mosaicism at this stage () makes a single cell unrepresentative of the entire embryo.

- Trophectoderm Biopsy (Day 5/6 Blastocyst):
- Timing: Conducted at the blastocyst stage ( post-fertilisation).
- Procedure: cells are excised from the trophectoderm layer (which gives rise to extra-embryonic tissues/placenta), deliberately avoiding the inner cell mass (ICM) that develops into the fetus.
- Advantages: Minimal impact on the embryo proper; provides multi-cell samples ( cells), which improves diagnostic accuracy, reduces PCR allele drop-out, and mitigates single-cell mosaicism artifacts.
- Limitations: Requires extended culture systems capable of sustaining embryos to the blastocyst stage; fewer embryos survive to Day .

- Minimally Invasive and Non-Invasive Approaches:
- Blastocentesis: Direct microneedle aspiration of fluid from the blastocoel cavity to analyse cell-free embryonic DNA (Gianaroli et al., Fertility and Sterility).
- Spent Culture Medium Analysis (niPGT): Collection and testing of cell-free embryonic DNA released into the spent in vitro culture droplets (Vera-Rodriguez et al., Human Reproduction, 2018; 33(4): 745–756).

Cytogenetic Methodologies: Fluorescence In Situ Hybridisation (FISH)
Mechanism of Action:
- Target blastomere interphase nuclei are immobilised onto a glass slide and chemically fixed.
- Nuclear DNA and fluorophore-labelled DNA probes are thermally denatured into single strands.
- Sequence-specific probes hybridise with target loci on specific chromosomes.
- Slides are visualised under an epifluorescence microscope equipped with narrow-band filter sets.
Diagnostic Applications:
- Historically used for sex determination in X-linked disorders.
- Testing for specific parental balanced structural rearrangements (PGT-SR).
- Historical PGT-A profiling common aneuploidies (chromosomes , , , , , , and ).
Normal Chromosomal Signals in Interphase Nuclei:
- Normal Male: , , (e.g., two Chromosome 16 signals).
- Normal Female: , , .
Technical Pitfalls and Causes of Misdiagnosis in Single-Cell FISH:
- Hybridisation Failure: Probe fails to bind, leading to a false diagnosis of monosomy or chromosomal loss.
- Overlapping Signals: Two distinct fluorescent signals lie on top of one another, appearing as a single signal and causing a false monosomy call.
- Split Signals: A single fluorescent probe signal splits into two distinct foci, mimicking a duplication or trisomy.
- Extraneous Cellular Contamination: Incomplete removal of maternally derived cumulus cells leads to extra maternal hybridisation signals.
Embryonic Chromosomal Patterns:
- Normal Diploid: Uniform complement of chromosomes across all blastomeres.
- Uniformly Aneuploid: Meiotic non-disjunction error producing an identical chromosomal abnormality (e.g., trisomy 21) across every cell of the embryo.
- Chromosomal Mosaicism: Presence of two or more distinct cytogenetic cell lines within a single embryo, resulting from post-zygotic mitotic errors during early cleavage divisions.
- Chaotic: Complete genomic instability where nearly every individual nucleus displays an erratic and divergent chromosomal constitution.
Molecular Methodologies: Polymerase Chain Reaction (PCR) and Single-Gene Testing
Fundamental PCR Principles: Repeated thermal cycling over three phases:
- Denaturation: Thermal denaturation of double-stranded DNA template at .
- Annealing: Hybridisation of specific synthetic oligonucleotide primers to flanking sequences at .
- Elongation: Enzymatic addition of complementary deoxynucleotide triphosphates (dNTPs) by a thermostable DNA polymerase (e.g., Taq polymerase) at .
Microsatellites / Short Tandem Repeat (STR) Markers:
- Repetitive, non-coding tandem DNA sequences (e.g., dinucleotide repeats) scattered across the genome.
- Highly polymorphic within human populations due to slipped-strand mispairing.
- Primers anneal to unique flanking single-copy DNA, producing variable product lengths that reflect distinct alleles (e.g., Allele 1 = , Allele 2 = , Allele 3 = , Allele 4 = ).
- Function as genetic fingerprints to track inheritance and identify extraneous DNA contamination.
Indirect Diagnosis via Linkage and Haplotype Phasing:
- Direct mutation detection in single-cell templates is prone to failure; genetic linkage analysis tracks polymorphic STR markers physically linked to the mutation.
- Closely linked STR markers flanking the pathogenic variant within a distance of are selected to minimise the probability of meiotic recombination or crossing-over ( recombination frequency).
- Phase Alleles: The specific set of STR marker alleles that reside on the same parental chromosome homologue as the pathogenic germline variant.
- Establishing phase requires reference DNA from an informative relative of known disease status (e.g., an affected child, grandparent, or sibling).

Worked Haplotype Analysis Example (Autosomal Dominant Disorder):
- Consider an affected mother carrying a dominant mutation and an unaffected father:
- STR 1 Marker: Mother has alleles and ; Father has alleles and .
- STR 2 Marker: Mother has alleles and ; Father has alleles and .
- Affected Son (Reference Relative): Inherited maternal alleles (STR 1) and (STR 2), alongside paternal alleles and .
- Phase Determination: The maternal mutant chromosome homologue carries the haplotype (phase alleles). The unaffected maternal chromosome carries the haplotype.
- Embryo Profiling:
- Embryos inheriting the maternal haplotype are diagnosed as Affected.
- Embryos inheriting the maternal haplotype are diagnosed as Unaffected.
Direct Mutation Detection Alongside Haplotype Analysis:
- When informative reference relatives are unavailable, phasing must be determined directly within the PGT cycle.
- Direct mutation detection (e.g., targeted sequencing) is combined with multi-point STR haplotyping across all generated embryos to infer which haplotype segregates with the mutation.
Inherent Technical Pitfalls of Single-Cell PCR:
- Amplification Failure: Complete absence of PCR amplification due to loss of the cell during manual micro-pipetting into the PCR reaction tube, anucleate blastomeres, or cellular degeneration.
- Allele Drop-Out (ADO): Random failure of one of the two alleles in a heterozygous cell to amplify during early PCR cycles. If the pathogenic mutant allele drops out, an affected embryo appears falsely unaffected (homozygous wild-type). Multiplex PCR incorporating multiple flanking STR markers is required to identify ADO events.
- Exogenous DNA Contamination: Amplification of foreign DNA (maternal cumulus cells, extraneous sperm, or operator shed DNA), masking the embryo's true genotype.
Special Clinical Applications: Saviour Siblings and Triplet Repeat Disorders
- Saviour Siblings and HLA Tissue Typing:
- Indicated when a living child suffers from a life-threatening bone marrow disorder (e.g., beta-thalassaemia, Fanconi anaemia) treatable via allogeneic haematopoietic stem cell transplantation.
- PGT is used to select embryos that are both free of the familial disease and an immunological Human Leukocyte Antigen (HLA) match to provide cord blood stem cells at birth.
- HLA Complex Architecture: Located on the short arm of human chromosome 6 ().
- Class I Antigens: HLA-A, HLA-B, HLA-C.
- Class II Antigens: HLA-DR, HLA-DQ, HLA-DP.

Mathematical Probability of a Transferable Match:
- Independent segregation of parental chromosome 6 homologues gives a () chance of an identical HLA match with the affected sibling.
- For an autosomal recessive condition, the probability of an embryo being unaffected (wild-type or carrier) is ().
- Cumulative probability of an embryo being both unaffected and HLA-matched: \text{ transferable embryos})\n\n- **Triplet Repeat Disorders and Dynamic Mutations:**\n - Conditions such as Huntington disease (CAG expansion in *HTT*) exhibit non-Mendelian dynamic expansions and clinical anticipation.\n - **Ethical Dilemma:** An individual at 50\% risk of Huntington disease may wish to avoid having an affected child without learning their own genetic status, preserving their "right not to know."\n - **Exclusion Testing:** Linkage analysis tracks whether the embryo inherited the chromosome 6/4 homologue from the affected grandparent versus the unaffected grandparent. Embryos inheriting the affected grandparental chromosome are discarded without determining whether the at-risk parent carries the expansion.\n - **Non-Disclosure Testing:**\n - Direct testing of the at-risk parent's mutation is performed by the diagnostic genetics laboratory, but results are strictly withheld from both the patient and the clinical team.\n - To avoid revealing whether the patient carries the mutation, "sham" embryo transfers are carried out if no unaffected embryos are available, maintaining the patient's confidentiality.\n\n\n# Whole Genome Amplification (WGA) and Advanced Diagnostic Platforms\n\n- **The Single-Cell Limitation:** A single diploid human cell contains approximately 6\text{--}7\,\text{pg} of genomic DNA, which is insufficient for comprehensive multi-locus molecular or cytogenetic profiling without prior whole genome amplification (WGA).\n\n- **Comparison of WGA Chemistries:**\n - **PCR-Based WGA (e.g., Linker-Adapter PCR / SurePlex / PicoPLEX / DOP-PCR):**\n - Uses enzymatic DNA fragmentation followed by ligation of universal adaptor sequences to both ends, followed by PCR with universal primers.\n - Generates short DNA fragments with uniform, even amplification across the entire genome.\n - Optimized for copy number variation (CNV) profiling, chromosomal microarray analysis, array CGH, and low-pass Next-Generation Sequencing.\n\n\n\n- **Multiple Displacement Amplification (MDA):**\n - Isothermal, non-PCR-based amplification utilizing bacteriophage Phi29 (\phi29) DNA polymerase and random hexamer primers.\n - Operates via a strand-displacement mechanism, generating long DNA fragments (>10\,\text{kb}) with high fidelity and proofreading activity.\n - Retains underlying sequence integrity, making it optimal for multi-locus STR sizing and SNP haplotyping; however, it can exhibit regional amplification bias that makes it less suitable for copy-number assessments.\n\n\n\n- **Preimplantation Genetic Haplotyping (PGH):**\n - Developed by Renwick et al. (*Reproductive BioMedicine Online*, 2010), demonstrating 127 diagnostic clinical cycles.\n - Leverages MDA-based WGA to yield sufficient DNA to test dozens of disease-linked STR markers simultaneously.\n - Standardizes PGT-M for specific conditions (such as the *CFTR* / F508del locus on chromosome 7) using an established panel of STR markers (D7S523, MS1, D7S2554, D7S2502, D7S486, MS3, D7S2460, IVS1CA, IVS8CA, CFSTR1, D7S2847, MS6, D7S843, D7S480, D7S650, D7S490), eliminating the need to design custom, patient-specific single-cell PCR tests.\n\n\n\n- **Array Comparative Genomic Hybridisation (aCGH):**\n - Employs competitive dual-colour hybridisation: test embryo DNA (labelled with Cy3 fluorophore) and normal reference DNA (labelled with Cy5 fluorophore) are hybridised onto a glass microarray containing mapped bacterial artificial chromosomes (BACs) or oligonucleotide probes.\n - Fluorescence intensity ratios (\log_2(\text{Ratio } \text{Cy3}/\text{Cy5})>+0.35<-0.35) indicates a deletion/monosomy.\n\n- **Next-Generation Sequencing (NGS) for Copy Number Profiling:**\n - Employs low-coverage / low-pass whole genome sequencing (\sim 0.01\times\text{--}0.1\times coverage depth).\n - Sequenced reads are aligned to the human reference genome and quantified across continuous genomic windows (bins).\n - Copy number is calculated using normalized read-depth (RD): significant drops in normalized read counts represent deletions/monosomies, while significant increases indicate duplications/trisomies.\n - **Clinical Milestone:** In 2013, Connor Levy became the first baby born following low-pass NGS-based embryo aneuploidy screening (work led by D. Wells, Treff et al., Martin et al.).\n\n\n\n\n# Single Nucleotide Polymorphism (SNP) Arrays and Karyomapping\n\n- **SNP Biology and Array Scale:**\n - The human genome contains approximately 10\,\text{million} Single Nucleotide Polymorphisms (SNPs).\n - Modern platforms, such as the Illumina HumanKaryomap-12 BeadChip, interrogate approximately 300{,}000 SNPs simultaneously.\n - At any given diallelic SNP locus (alleles A and B), four discrete categorical genotype calls are generated: AAABBBNC).\n\n- **Karyomapping Mechanics:**\n - Developed by Alan H. Handyside et al. (*Journal of Medical Genetics*).\n - A high-density genome-wide linkage methodology that maps parent-of-origin meiotic crossovers across all 24 chromosomes.\n - **Sample Requirements:** Genomic DNA from both parents and an informative reference relative of known genetic status (e.g., an affected or unaffected child, sibling, or grandparent).\n - Evaluates informative SNPs (where one parent is heterozygous ABAABB) to determine which parental chromosome homologue has been transmitted to each embryo.\n\n- **Integrated Cytogenetic Profiling from SNP Arrays:**\n - SNP arrays provide concurrent cytogenetic data (PGT-A / PGT-SR) alongside PGT-M by evaluating two biophysical parameters:\n - **Log R Ratio (LRR):** Measures total normalised fluorescence intensity. A value of 0.02n); positive shifts indicate copy gains, while negative shifts indicate copy losses.\n - **B-Allele Frequency (BAF):** Quantifies the proportion of the total hybridisation signal attributable to the B allele (\text{Signal}_B / (\text{Signal}_A + \text{Signal}_B)).\n\n\n\n- **Cytogenetic Signatures on SNP Microarrays:**\n - **Normal Diploidy (2n0.00.0AA0.5AB1.0BB).\n - **Trisomy (3n0.00.0AAA0.33AAB0.67ABB1.0BBB).\n - **Hemizygous Deletion / Monosomy (1n-0.5-1.0AB0.0A1.0B).\n - **Homozygous Deletion (0n-2.0-10.0); complete absence of hybridisation signal.\n - **Copy-Neutral Loss of Heterozygosity (CN-LOH) / Uniparental Disomy (UPD):** LRR remains neutral at 0.0AB0.50.01.0 signals. This pattern reveals regions of uniparental isodisomy.\n\n- **Platform Convergence:** SNP haplotyping (e.g., Karyomapping, Haplarithmisis) and comprehensive targeted NGS allow simultaneous detection of monogenic disorders, structural rearrangements, and aneuploidies on a single diagnostic platform.\n\n\n# Diagnostic Pitfalls, Mosaicism, and Mitochondrial Inheritance\n\n- **Systematic Taxonomy of PGT Misdiagnosis:** Wilton et al. (*Human Reproduction*, 2009; 24(5): 1221–1228) classified causes of PGT misdiagnosis into distinct functional categories:\n - **Human Errors:**\n - Unprotected sexual intercourse during the active IVF/PGT treatment cycle (resulting in natural conception of an unselected embryo).\n - Mislabelling of sample collection tubes, glass slides, or storage cryovials.\n - Misidentification of embryos during micromanipulation or transfer.\n - Misinterpretation of raw diagnostic data or analytical software reports.\n - Accidental transfer of an affected or aneuploid embryo.\n - Design or ordering errors in sequence-specific molecular primers or FISH probes.\n - Erroneous segregation or linkage phasing analysis.\n - **Intrinsic Embryonic Factors:**\n - Chromosomal mosaicism (biopsied cell does not represent the inner cell mass).\n - True constitutional embryonic haploidy.\n - Uniparental disomy (UPD).\n - **Extrinsic Technical Errors:**\n - Extraneous maternal cellular contamination (unstripped cumulus cells).\n - Paternal contamination (multiple sperm bound to the zona pellucida in non-ICSI cycles).\n - Operator contamination from exfoliated skin or respiratory droplets.\n - PCR carry-over contamination from previously amplified amplicons.\n - Fluorophore degradation, photobleaching, or chemical failure of hybridization probes.\n - **Intrinsic Technical Errors:**\n - PCR Allele Drop-Out (ADO).\n\n- **Chromosomal Mosaicism in Preimplantation Embryos:**\n - Mosaicism occurs when post-zygotic mitotic errors arise during early embryonic divisions.\n - **Prevalence:** Identified in up to 90\%50\% of Day 5 blastocysts (Wells et al.; Fiorentino et al.).\n - **Clinical Implications:** A single biopsied trophectoderm sample may not accurately reflect the cytogenetic status of the unbiopsied cells, particularly the inner cell mass that forms the fetus.\n - **ESHRE Good Practice Recommendations (2022):** Provide guidelines for classifying mosaic embryos (low-level vs high-level, segmental vs whole-chromosome) and establishing prioritisation pathways when no fully euploid embryos are available.\n\n- **Mitochondrial Genetic Disorders:**\n - **Mitochondrial DNA (mtDNA) Biology:** A human oocyte contains approximately 100{,}000 copies of the circular mitochondrial genome.\n - **Heteroplasmy:** The coexistence of mutated and wild-type mtDNA genomes within a single cell or tissue.\n - **Threshold Effect:** Pathogenic phenotypes only manifest when the proportion of mutated mtDNA exceeds a critical threshold (typically 60\%90\%$$ depending on the specific mutation and tissue type).
PGT Limitations for mtDNA: Blastomere or trophectoderm biopsies may not accurately predict future fetal tissue heteroplasmy due to mitochondrial genetic bottlenecks and random segregation drift during organogenesis.
- Mitochondrial Replacement Therapy (MRT / "Three-Parent IVF"):
Maternal Spindle Transfer (MST): The nuclear meiotic spindle apparatus is extracted from an unfertilised oocyte carrying mutated mtDNA, transferred into an enucleated donor oocyte with healthy mitochondria, and subsequently fertilised via ICSI.
Pronuclear Transfer (PNT): The mother's oocyte is fertilised in vitro; both pronuclei are extracted on Day 1 and transferred into an enucleated donor zygote containing healthy mitochondria.
Clinical Milestone: First live birth following spindle transfer reported by John Zhang et al. in 2016; both MST and PNT are legally permissible under statutory HFEA regulatory licensing in the United Kingdom.

Ethical, Regulatory, and Future Frontiers in PGT
Ethical Challenges and Clinical Boundaries:
- Late-Onset Disorders and Cancer Predispositions: Debates surrounding the selection against non-fully-penetrant conditions or adult-onset diseases (e.g., BRCA1/2, Huntington disease, hereditary nonpolyposis colorectal cancer).
- Sex Selection: Selection for non-medical reasons ("family balancing") is prohibited under UK HFEA regulations; permissible strictly to avoid severe X-linked disorders when direct mutation detection is unavailable.
- Saviour Siblings: Ethical debates over selecting an embryo to serve as a compatible tissue donor for an existing sibling.
- Polygenic Risk Scoring (PRS): Emerging commercial offerings to rank embryos based on polygenic scores for complex multifactorial traits and adult chronic diseases (e.g., schizophrenia, diabetes, cardiovascular diseases, cosmetic traits), raising serious ethical concerns regarding safety and eugenics.
- Germline Genome Editing: Theoretical application of CRISPR-Cas9 or base editors to directly correct pathogenic variants in human embryos, raising technical concerns over off-target cuts and mosaicism, as well as significant international bioethical debate.
Future Diagnostic Directions:
- Universal Testing Platforms: Movement toward unified workflows where low-pass whole genome sequencing or high-density SNP arrays simultaneously evaluate PGT-M, PGT-SR, and PGT-A on a single biopsy.
- Non-Invasive PGT: Continued development of cell-free embryonic DNA analysis from spent culture media (niPGT) to replace invasive cellular biopsies.
- Integration of Expanded Carrier Screening (ECS): Routine use of pan-ethnic preconception carrier screening, feeding directly into clinical PGT options before pregnancy is initiated.